‘Tackling hepatitis C: Moving towards an integrated policy approach’, a report published by The Economist Intelligence Unit (EIU) today reveals that many countries around the world have been slow to respond with national policies on hepatitis C despite recent government pledges to fight the disease. The hepatitis C virus remains the leading cause of liver cancer, liver disease and liver transplantation placing a huge burden on patients' lives and healthcare systems.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400562-janssen-new-reports-hepatitis-c
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or were treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you may be eligible for compensation from a class action Settlement
A $190 million dollar proposed Settlement has been reached that offers payments to eligible members of The Levy Settlement Class.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7281851-dr-nikita-levy-patients-class-action-settlement/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
CVS Caremark Corporation (NYSE: CVS) announced today that it is changing its corporate name to CVS Health to reflect its broader health care commitment and its expertise in driving the innovations needed to shape the future of health.
As a further demonstration of its commitment to health, CVS Health also announced the end of tobacco sales at CVS/pharmacy as of September 3, nearly a month ahead of the previously targeted date of October 1. In February, the company announced that it would end the sale of cigarettes and tobacco products at its CVS/pharmacy stores, making CVS/pharmacy the first and only national pharmacy chain to take this step in support of the health and well-being of its patients and customers.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7308951-cvs-caremark-announces-corporate-name-change-to-cvs-health/
Many people equate a conversation about hospice as being told they must give up. However, more than 1 million people across the nation have learned just the opposite. They’ve been touched by the National Hospice and Palliative Care Organization’s “Moments of Life: Made Possible by Hospice” campaign since its launch on May 15, 2014. The campaign’s intent is to debunk this myth, and show that hospice focuses on compassionate, person-centered care, which enables special moments and memories at the end of life for patients and loved ones.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7154752-national-hospice-and-palliative-care-organization-nhpco-moments-of-life-psa/
The European Head and Neck Society (EHNS) today announces European-wide ‘Early Diagnosis Days’ taking place on Wednesday 24 September as part of this year’s Head and Neck Cancer Awareness Week (22–26 September). This follows the success of the 2013 campaign, where nearly 100 ‘Early Diagnosis Days’ took place. More than 5,000 patients were seen by a healthcare provider in 1 day, resulting in a referral rate of approximately 5% and multiple diagnoses of the disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762527-EHNS-early-diagnosis-days/
In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
Understanding the burden of metastatic breast cancer (MBC), and the toll it takes on patients and their loved ones, Eisai Inc. announced today the launch of mbcInfoCenter.com, a new online portal designed to provide important resources that may help women with MBC manage their disease and focus on their health and wellness.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7342251-eisai-launches-mbc-infocenter-for-women-with-metastatic-breast-cancer/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Rosecrance, one of the country’s leading teen substance abuse treatment centers, has launched a traveling art exhibit to help parents understand teenagers’ points of view about pressures they encounter and how they are faced with the potential to use, and abuse, substances. Developed by teen patients participating in an art therapy program at Rosecrance’s adolescent campus in Rockford, IL, “In My Shoes” encourages parents to understand their teen’s point of view and actively parent to help teens navigate today’s confusing environment.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7348551-rosecrance-s-in-my-shoes-traveling-art-exhibit-parents-teenagers-prevent-substance-abuse/
With gout incidence on the rise, an increasing number of medical professionals, across multiple fields of practice, will continue to be exposed to patients who suffer from gout and are seeking an accurate diagnosis and treatment. However, despite the availability of the “Guidelines for the Management of Gout” by the American College of Rheumatology (ACR), there are many inconsistencies in how gout is diagnosed, treated and discussed by medical professionals. Conflicting messages and treatment recommendations can contribute to confusion, and even lack of compliance, on behalf of the patient – particularly when gout is connected with comorbid conditions, such as kidney disease, heart disease or diabetes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7362551-gout-uric-acid-education-society-guaes-roundtable-consensus-paper/
